Immunological substance testing on human lymphatic micro-organoids in vitro.

Pharmaceutical drugs and compounds used for consumer products may bear the risk of unexpected immuno-toxicological side effects, such as sensitization, allergy, anaphylaxis or immunogenicity. Modern biopharmaceuticals with high potency and target specificity, like antibodies and cytokines need to be tested for their therapeutical doses, their exposition regimens and their immune functionality prior to first-in-man applications. For the latter, existing in vitro tests and animal models do not sufficiently reflect the complexity and specificity of the human immune system. Even novel humanised animal models have limitations in their systemic reactions. Monolayer or suspended cell culture possesses neither tissue functionality nor organ physiology, and also cannot be used for long term culture and experiments. In contrast, solid tissue biopsies, e.g. tonsil preparations of tonsillitis patients typically show inflammatory artefacts and degrade in long term culture due to preparation-induced damage. The construction of tissue-like structures in vitro, so-called "micro-organoids", can overcome these limitations. Key structures of secondary lymphatic organs, e.g. lymph nodes or the spleen are the primary lymphatic follicles and germinal centres, in particular during the "activated state" of an inflammation or infection. To remodel lymphatic follicles, functional and structural cells, e.g. lymphoid cells derived from peripheral blood mononuclear cells (PBMCs) and stromal cells need to be combined with biogenic or artificial matrices and scaffolds to produce a suitable 3D tissue-mimicking environment. Therefore, a unique human lymph node model (HuALN) was designed to operate over several weeks, and allow long term and repeated drug exposure to induce and monitor both cellular and humoral immune responses. Cellular immunity is monitored, for example, by cytokine release patterns; humoral immunity is analysed, for example, by B cell activation, plasma cell formation and antibody secretion profiles (IgM and IgG). Moreover, cellular composition and micro-organoid formation are analysed by flow cytometry, histology and in situ imaging.

[1]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[2]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[3]  Scott N. Mueller,et al.  Stromal cell contributions to the homeostasis and functionality of the immune system , 2009, Nature Reviews Immunology.

[4]  Ulrich H. von Andrian,et al.  Homing and cellular traffic in lymph nodes , 2003, Nature Reviews Immunology.

[5]  R. Jonsson,et al.  Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. , 2003, Arthritis and rheumatism.

[6]  K. Shakesheff,et al.  Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing. , 2009, Regenerative medicine.

[7]  J. Nyhus,et al.  Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). , 2006, Vaccine.

[8]  Burkhard Ludewig,et al.  Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence , 2008, Nature Reviews Immunology.

[9]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[10]  Takeshi Watanabe,et al.  Generation of a synthetic lymphoid tissue–like organoid in mice , 2004, Nature Biotechnology.

[11]  B. Schraven,et al.  CD28 superagonists: what makes the difference in humans? , 2008, Immunity.

[12]  J. Cyster,et al.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.

[13]  Uwe Marx,et al.  A human lymph node in vitro--challenges and progress. , 2006, Artificial organs.

[14]  S. Maier,et al.  Endogenous Glucocorticoids Play a Positive Regulatory Role in the Anti-Keyhole Limpet Hemocyanin In Vivo Antibody Response , 2001, The Journal of Immunology.

[15]  I Kimber,et al.  Alternative approaches to the identification and characterization of chemical allergens. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[16]  A. Holmes,et al.  Assuring consumer safety without animals , 2009, Organogenesis.

[17]  L. Griffith,et al.  Capturing complex 3D tissue physiology in vitro , 2006, Nature Reviews Molecular Cell Biology.

[18]  Domenico Ribatti,et al.  Setting the stage: an anatomist's view of the immune system. , 2004, Trends in immunology.

[19]  S. Sakuma,et al.  Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. , 2001, International immunopharmacology.

[20]  M. Wadhwa,et al.  “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.

[21]  S. Pals,et al.  Triple check for antigen specificity of B cells during germinal centre reactions. , 1997, Immunology today.

[22]  J. Hubbell,et al.  Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering , 2005, Nature Biotechnology.

[23]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[24]  R J Fielder,et al.  Local lymph node assay - validation, conduct and use in practice. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[25]  C. Berek,et al.  The dynamic structure of the germinal center. , 1998, Immunology today.

[26]  Thomas Hartung,et al.  Chemical regulators have overreached , 2009, Nature.

[27]  Uwe Marx,et al.  Drug testing in vitro : breakthroughs and trends in cell culture technology , 2006 .

[28]  M. Teixeira,et al.  Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC , 2005, Journal of Neuroimmunology.